Expanding indications for sodium fumarate anti-hypoxia infusion solution in kidney cancer surgery: literature review
S. V. Popov,
A. V. Dunaev,
R. G. Guseynov,
K. V. Sivak,
T. A. Lelyavina,
E. V. Potapova,
A. Yu. Vinokurov,
N. S. Bunenkov,
I. O. Shmidt,
R. O. Grushevskiy,
E. A. Malyshev,
A. H. Beshtoev https://doi.org/10.17650/1726-9776-2025-21-2-167-179
Abstract
This literature review is devoted to the urgent problem of organ-saving surgery for kidney cancer: hypoxic-ischemic changes in the spared renal tissue and possibilities of their prevention through the use of the succinate-forming drug sodium fumarate 15 %.
About the Authors
S. V. Popov
St. Luka’s Clinical Hospital;
S.M. Kirov Military Medical Academy, Ministry of Defense of Russia;
Saint Petersburg Medical and Social Institute
Russian Federation
Russian Federation
Sergey Valer’evich Popov
46 Chugunnaya St., Saint Petersburg 194044;
6 Lebedeva St., Saint Petersburg, 194044;
Lit. A, 72 Kondratievsky Prospekt, Saint Petersburg 195271
A. V. Dunaev
I.S. Turgenev Orеl State University
Russian Federation
Russian Federation
95 Komsomol’skaya St., Orеl 302026
R. G. Guseynov
St. Luka’s Clinical Hospital;
Saint Petersburg Medical and Social Institute
Russian Federation
Russian Federation
46 Chugunnaya St., Saint Petersburg 194044;
Lit. A, 72 Kondratievsky Prospekt, Saint Petersburg 195271
K. V. Sivak
St. Luka’s Clinical Hospital;
A.A. Smorodintsev Research Institute of Influenza
Russian Federation
Russian Federation
46 Chugunnaya St., Saint Petersburg 194044;
15/17 Professora Popova St., Saint Petersburg 197376
T. A. Lelyavina
St. Luka’s Clinical Hospital;
V.A. Almazov National Medical Research Centre
Russian Federation
Russian Federation
46 Chugunnaya St., Saint Petersburg 194044;
2 Akkuratova St., Saint Petersburg 197341
E. V. Potapova
I.S. Turgenev Orеl State University
Russian Federation
Russian Federation
95 Komsomol’skaya St., Orеl 302026
A. Yu. Vinokurov
I.S. Turgenev Orеl State University
Russian Federation
Russian Federation
95 Komsomol’skaya St., Orеl 302026
N. S. Bunenkov
St. Luka’s Clinical Hospital;
V.A. Almazov National Medical Research Centre
Russian Federation
Russian Federation
46 Chugunnaya St., Saint Petersburg 194044;
2 Akkuratova St., Saint Petersburg 197341
I. O. Shmidt
St. Luka’s Clinical Hospital
46 Chugunnaya St., Saint Petersburg 194044
R. O. Grushevskiy
St. Luka’s Clinical Hospital
46 Chugunnaya St., Saint Petersburg 194044
E. A. Malyshev
St. Luka’s Clinical Hospital
Russian Federation
Russian Federation
46 Chugunnaya St., Saint Petersburg 194044
A. H. Beshtoev
St. Luka’s Clinical Hospital
Russian Federation
Russian Federation
References
1. Merabishvili V.M., Poltorackiy A.N., Nosov A.K. et al. The state of oncology care in Russia. Kidney cancer (morbidity, mortality, index of accuracy, one-year and year-by-year mortality, histological structure). Part 1. Onkourologiya = Cancer Urology 2021;17(2):182–94. (In Russ.). DOI: 10.17650/1726-9776-2021-17-2-182-194
2. State of oncological care in Russia in 2021. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2022. 239 p. (In Russ.).
3. Du Z., Chen W., Xia Q. et al. Trends and projections of kidney cancer incidence at the global and national levels, 1990–2030: a Bayesian age-period-cohort modeling study. Biomark Res 2020;8:16. DOI: 10.1186/s40364-020-00195-3
4. Saad A.M., Gad M., Al-Husseni M.J. et al. Trends in renal-cell carcinoma incidence and mortality in the United States in the last 2 decades: a SEER-based study. Clin Genitourin Cancer 2019;17(1):46–57.e5. DOI: 10.1016/j.clgc.2018.10.002
5. Sung H., Ferlay J., Siegel R. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI: 10.3322/caac.21660
6. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023.
7. Astashov V.L., Shapovalov V.V., Balanyuk V.V. et al. First experience of superselective embolization of renal arteries supplying the tumor with subsequent laparoscopic kidney resection. Onkourologiya = Cancer Urology 2021;17(3):30–6. (In Russ.). DOI: 10.17650/1726-9776-2021-17-3-30-36
8. Volkova M.I., Ridin V.A., Cherniayev V.A. et al. Is technically complicated partial nephrectomy justified in renal cell carcinoma patients with normal contralateral kidney? Onkourologiya = Cancer Urology 2019;15(4):39–49. (In Russ.). DOI: 10.17650/1726-9776-2019-15-4-39-49
9. Kulchenko N.G. Treatment of localized renal cancer. Uzhno-Rossiyskiy onkologicheskiy zhurnal = South Russian Journal of Cancer 2020;1(1):69–75. (In Russ.). DOI: 10.37748/2687-0533-2020-1-1-6
10. Renal parenchymal cancer. Clinical guidelines. Moscow, 2022. (In Russ.).
11. Shormanov I.S., Los M.S. Approaches to kidney anti-ischemic protection in organ-preserving surgical treatment of patients with renal cell cancer. Urologicheskie vedomosti = Urological Reports (Saint Petersburg) 2019;9(3):39–47. (In Russ.). DOI: 10.17816/uroved9339-47
12. Breau R.H., Kapoor A., Nash D.M. et al. Partial vs. radical nephrectomy and the risk of all-cause mortality, cardiovascular, and nephrological outcomes. Can Urol Assoc J 2020;14(10):337–45. DOI: 10.5489/cuaj.6436
13. Campbell S.C., Clark P.E., Chang S.S. et al. Renal mass and localized renal cancer: evaluation, management and follow-up: AUA guideline: Part I. J Urol 2021;206(2):199–208. DOI: 10.1097/JU.0000000000001911
14. Escudier B., Porta C., Schmidinger M. et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30(5):706–20. DOI: 10.1093/annonc/mdw328
15. Janssen M.W.W., Linxweiler J., Terwey S. et al. Survival outcomes in patients with large (>/=7cm) clear cell renal cell carcinomas treated with nephron-sparing surgery versus radical nephrectomy: results of a multicenter cohort with long-term follow-up. PLoS One 2018;13(5):e0196427. DOI: 10.1371/journal.pone.0196427
16. Li C.C., Chien T.M., Huang S.P. et al. Single-site sutureless partial nephrectomy for small exophytic renal tumors. J Clin Med 2020;9(11):3658. DOI: 10.3390/jcm911365.8
17. Liu H., Kong Q.F., Li J. et al. A meta-analysis for comparison of partial nephrectomy vs. radical nephrectomy in patients with pT3a renal cell carcinoma. Transl Androl Urol 2021;10(3):1170–8. DOI: 10.21037/tau-20-1262
18. Ljunberg B., Albiges L., Abu-Ghanem Y. et al. European association of urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol 2019;75:799–810. DOI: 10.1016/j.eururo.2019.02.011
19. Palacios D., Zabor E., Munoz-Lopez C. et al. Does reduced renal function predispose to cancer-specific mortality from renal cell carcinoma? Eur Urol 2021;79(6):774–780. DOI: 10.1016/j.eururo.2021.02.035
20. Patel S.H., Uzzo R.G., Larcher A. et al. Oncologic and functional outcomes of radical and partial nephrectomy in pT3a pathologically upstaged renal cell carcinoma: a multi-institutional analysis. Clin Genitourin Cancer 2020;18(6):e723–9. DOI: 10.1016/j.clgc.2020.05.002
21. Spinelli J.B., Rosen P.C., Sprenger H.G. et al. Fumarate is a terminal electron acceptor in the mammalian electron transport chain. Science 2021;374(6572):1227–37. DOI: 10.1126/science.abi7495
22. Dzhalilov I.B., Osetnik V.K., Mamizhev E.M. et al. Normotension – new approach in laparoscopic partial nephrectomy. Onkourologiya = Cancer Urology 2020;16(2):36–43. (In Russ.). DOI: 10.17650/1726-9776-2020-16-2-36-43
23. Nosov A.K., Petrov S.B., Lushina P.A. et al. Fast track for partial nephrectomy. Onkourologiya = Cancer Urology 2019;15(3):47–55. (In Russ.). DOI: 10.17650/1726-9776-2019-15-3-47-55
24. Amparore D., Pecoraro A., Checcucci F. et al. Comparison between minimallyinvasive partial and radical nephrectomy for the treatment of clinical T2 renal masses: results of a 10-year study in a tertiary care center. Minerva Urol Nephrol 2021;73(4):509–17. DOI: 10.23736/S2724-6051.21.04390-1
25. Antonelli A., Cindolo L., Sandri M. et al. Safety of onvs off-clamp robotic partial nephrectomy: per-protocol analysis from the data of the CLOCK randomized trial. World J Urol 2020;38(5):1101–8. DOI: 10.1007/s00345-019-02879-4
26. Chang K.D., Raheem A.A., Kim K.H. et al. Functional and oncological outcomes of open, laparoscopic and robotassisted partial nephrectomy: a multicentre comparative matched-pair analyses with a median of 5 years’ follow-up. BJU Int 2018;22(4):618–26. DOI: 10.1111/bju.14250
27. Chenam A., Lau C. Management of small renal masses. Cancer Treat Res 2018;175:105–26. DOI: 10.1007/978-3-319-93339-9_5
28. Dong W., Wu J., Suk-Ouichai C. et al. Ischemia and functional recovery from partial nephrectomy: refined perspectives. Eur Urol Focus 2018;4(4):572–8. DOI: 10.1016/j.euf.2017.02.001
29. Melgarejo J., Yang W., Thijs L. et al. Association of fatal and nonfatal cardiovascular outcomes with 24-hour mean arterial pressure. Hypertension 2021;77(1):39–48. DOI: 10.1161/HYPERTENSIONAHA.120.14929
30. Osetnik V.K., Orlova R.V., Gadzhiev N.K. et al. Laparoscopic partial nephrectomy: results of various surgery techniques. Onkourologiya = Cancer Urology 2022;18(1):17–23. (In Russ.). DOI: 10.17650/1726-9776-2022-18-1-17-23
31. Dagenais J., Bertolo R., Garisto J. et al. “At-risk” kidney: how surgical factors influence renal functional preservation after partial nephrectomy. Int J Urol 2019;26(5):565–70. DOI: 10.1111/iju.13930
32. Gonsalez S.R., Cortês A.L., Silva R.C.D. et al. Acute kidney injury overview: From basic findings to new prevention and therapy strategies. Pharmacol Ther 2019;200:1–12. DOI: 10.1016/j.pharmthera.2019.04.001
33. Kormann R., Kavvadas P., Placier S. et al. Periostin promotes cell proliferation and macrophage polarization to drive repair after AKI. J Am Soc Nephrol 2020;31(1):85–100. DOI: 10.1681/ASN.2019020113
34. Martini A., Sfakianos J.P., Paulucci D.J. et al. Predicting acute kidney injury after robot-assisted partial nephrectomy: implications for patient selection and postoperative management. Urol Oncol 2019;37(7):445–51. DOI: 10.1016/j.urolonc.2019.04.018
35. Melo Ferreira R., Sabo A.R., Winfree S. et al. Integration of spatial and single-cell transcriptomics localizes epithelial cell-immune cross-talk in kidney injury. JCI Insight 2021;6(12):147703. DOI: 10.1172/jci.insight.147703
36. Popov S.V., Guseinov R.G., Skryabin O.N., Sivak K.V. Warm ischemia of the kidney. Moscow: GEOTAR-Media, 2020. 271 p. (In Russ.).
37. Popov S.V., Guseynov R.G., Pomeshkin E.V. et al. Perioperative acute kidney injury in surgical treatment of renal cancer: pathogenesis, therapy of early and late complications. Issledovaniya i praktika v meditsine = Research and Practical Medicine Journal 2023;10(2):104–17. (In Russ.). DOI: 10.17709/2410-1893-2023-10-2-10
38. Balzer M.S., Doke T., Yang Y.W. et al. Single-cell analysis highlights differences in druggable pathways under-lying adaptive or fibrotic kidney regeneration. Nat Commun 2022;13(1):4018. DOI: 10.1038/s41467-022-31772-9
39. Guseynov R.G. Increasing efficacy of pharmacological protection of the kidney during nephron-sparing interventions (experimental study). Dis. … candidate of medical sciences. Saint Petersburg, 2020. 257 p. (In Russ.).
40. Popov S.V., Guseynov R.G., Skryabin O.N. Evaluation of the results of sodium fumarate, furosemide, and mannitol on the initiation and outcome of renal warm ischemia in an experimental study. Urologiia = Urology 2022;(2):18–26. (In Russ.).
41. Smirnov A.V., Rumyantsev A.Sh. Acute kidney disease. Part I. Nefrologiya = Nephrology (Saint Petersburg) 2020;24(1):67–95. (In Russ.). DOI: 10.36485/1561-6274-2020-24-1-67-95
42. Guseynov R.G., Popov S.V., Gorshkov A.N. et al. Effects of the of renal warm ischemia time on the recovery of filtration function in the experiment. Urologiia = Urology 2017;(6):20–9. (In Russ.).
43. Chen Y.L., Li H.K., Wang L. et al. No safe renal warm ischemia time – the molecular network characteristics and pathological features of mild to severe ischemia reperfusion kidney injury. Front Mol Biosci 2022;9:1006917. DOI: 10.3389/fmolb.2022.1006917
44. Lai D., Wang L., Li J.R. et al. Transcriptional progressive patterns from mild to severe renal ischemia/reperfusion-induced kidney injury in mice. Front Genet 2022;13:874189. DOI: 10.3389/fgene.2022.874189
45. Zhang J., Shen R., Lin H. et al. Effects of contralateral nephrectomy timing and ischemic conditions on kidney fibrosis after unilateral kidney ischemia-reperfusion injury. Ren Fail 2022;44(1):1568–84. DOI: 10.1080/0886022X.2022.2126790
46. Shabanov P.D. Chronicles of St. Petersburg pharmacology (on 210th anniversary of the Department of Pharmacology of the St. Petersburg State Military Medical Academy. Eksperimentalnaya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology 2009;72(4):46–51. (In Russ.).
47. Shabanov P.D. Department of Pharmacology at the Imperial Medical and Surgical (Military Medical) Academy: History of the second century of existence (1899–2000). Psikhofarmakologiya i biologicheskaya narkologiya = Psychopharmacology and Biological Narcology 2023;14(2):113–8. (In Russ.). DOI: 10.17816/phbn501756
48. Shabanov P.D. Department of Pharmacology of the Military Medical Academy in the 21st century: New achievements based on historical traditions (2000–2023). Psikhofarmakologiya i biologicheskaya narkologiya = Psychopharmacology and Biological Narcology 2023;14(4):263–84. (In Russ.). DOI: 10.17816/phbn623094
49. Shabanov P.D. Creator of the concept of antihypoxants and actoprotectors: on the occasion of the 100th anniversary of Professor V.M. Vinogradov. Psikhofarmakologiya i biologicheskaya narkologiya = Psychopharmacology and Biological Narcology 2024;15(1):79–90. (In Russ.). DOI: 10.17816/phbn625959
50. Methodological recommendations for biomedical (preclinical) study of the antihypoxic activity of drugs under the editorship. Ed.: N.N. Karkishchenko. Moscow, 2017. 98 p. (In Russ.).
51. Lukyanova L.D. Signal mechanisms of hypoxia. Moscow: RAN, 2019. (In Russ.).
52. De C. Fonseca M., Aguiar C.J., da Rocha Franco J.A. et al. GPR91: Expanding the frontiers of Krebs cycle intermediates. Nephrologiya = Nephrology 2017;21(1):9–18. (In Russ.). DOI: 10.24884/1561-6274-2017-21-1-9-18
53. Russian register of medicines. Encyclopedia of medicines: Annual collection. Moscow: Vedanta, 2019. 860 p. (In Russ.).
54. Drug reference “Russian register of medicines.” 2000–2024. (In Russ.).
55. Blood substitutes, blood components, post-transfusion reactions and complications: Reference for doctors. Eds.: B.B. Bakhovadinova, B.A. Barysheva. Saint Petersburg: Optima, 2018. 288 p. (In Russ.).
56. Selivanov E.A., Slepneva L.V., Alekseeva N.N. et al. Experience in the use of polyoxifumarin for treatment hypovolemia of children. MEDLINE.RU 2010;11:1–11. (In Russ.).
57. Selivanov E.A., Slepneva L.V., Alekseeva N.N. et al. Fumaratecontaining infusion solutions as a tool of choice in emergency medical care. Meditsina ekstremalnykh situatsiy = Extreme Medicine 2012;(1):85–94. (In Russ.).
58. Sofronov G.A., Selivanov E.A., Khanevich M.D. et al. Application of infusions of anti-hypoxic drug solutions in surgery. Vestnik Natsionalnogo mediko-khirurgicheskogo tsentra im. N.I. Pirogova = Bulletin of Pirogov National Medical and Surgical Center 2011;6(1):87–91. (In Russ.).
59. Verbitsky V.G., Sukhomlin A.K., Slepneva L.V. Possibilities of application of infusion antihypoxant Konfumin in therapy of posthemorrhagic disturbances of homeostasis during gastroduodenal bleedings. Ekstrennaya meditsina = Emergency Medicine 2015;(3):42–50. (In Russ.).
60. Velikanova L.K. Osmoreceptors. Novosibirsk, 1985. 48 p. (In Russ.).
61. Bogoyavlenskiy I.F., Zaks I.O. Use of hypertonic sodium chloride solutions in intensive care and disaster medicine. Anesteziologiya i reanimatologiya = Russian Journal of Anesthesiology and Reanimatology 1994;(2):59–63. (In Russ.).
62. Finder D.R., Hardin C.D. Transport and metabolism of exogenous fumarate and 3-phosphoglycerate in vascular smooth muscle. Mol Cell Biochem 1999;195(1–2):113–21. DOI: 10.1023/a:1006976432578
63. Koivunen P., Hirsilä M., Remes A.M. et al. Inhibition of hypoxiainducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 2007;282(7):4524–32. DOI: 10.1074/jbc.M610415200
64. Kierans S.J., Taylor C.T. Regulation of glycolysis by the hypoxiainducible factor (HIF): implications for cellular physiology. J Physiol 2021;599(1):23–37. DOI: 10.1113/JP280572
Review
For citations:
Popov S.V., Dunaev A.V., Guseynov R.G., Sivak K.V., Lelyavina T.A., Potapova E.V., Vinokurov A.Yu., Bunenkov N.S., Shmidt I.O., Grushevskiy R.O., Malyshev E.A., Beshtoev A.H. Expanding indications for sodium fumarate anti-hypoxia infusion solution in kidney cancer surgery: literature review. Cancer Urology. 2025;21(2):167-179. (In Russ.) https://doi.org/10.17650/1726-9776-2025-21-2-167-179
Views:
102
Email this article 